Alpha 2.0
Login Register
» Authors » A Benner

A Benner

Explore the profile of A Benner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 111
Citations 3506
Followers 0
Related Specialties
Oncology
Hematology
General Surgery
Top 10 Co-Authors
A D Ho
H Dohner
R F Schlenk
P Kienle
K Dohner
H Goldschmidt
P Lichter
J Weitz
M von Knebel Doeberitz
C Herfarth
Published In
Leukemia
Blood
Bone Marrow Transplant
Br J Cancer
Int J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study
Safi S, Krzykalla J, Hoffmann H, Benner A, Bischoff H, Eichhorn M, et al.
Pulmonology . 2024 Apr; 31(1):2416803. PMID: 38614857
Introduction And Objectives: Adjuvant platinum-based chemotherapy for completely resected non-small cell lung cancer is associated with modest improvement in survival; nevertheless, no validated biomarker exists for predicting the benefit or...
2.
Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
Schlenk R, Weber D, Krzykalla J, Kindler T, Wulf G, Hertenstein B, et al.
Sci Rep . 2023 Sep; 13(1):14809. PMID: 37684299
The aim of this randomized clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with non-intensive chemotherapy in older unfit patients (> 60 years) with...
3.
The human embryonic genome is karyotypically complex, with chromosomally abnormal cells preferentially located away from the developing fetus
Griffin D, Brezina P, Tobler K, Zhao Y, Silvestri G, Mccoy R, et al.
Hum Reprod . 2022 Nov; 38(1):180-188. PMID: 36350568
Study Question: Are chromosome abnormalities detected at Day 3 post-fertilization predominantly retained in structures of the blastocyst other than the inner cell mass (ICM), where chromosomally normal cells are preferentially...
4.
The association of new-onset diabetes with subsequent diagnosis of pancreatic cancer-novel use of a large administrative database
White M, Sheka A, LaRocca C, Irey R, Ma S, Wirth K, et al.
J Public Health (Oxf) . 2022 Nov; 45(2):e266-e274. PMID: 36321614
Background: Screening options for pancreatic ductal adenocarcinoma (PDAC) are limited. New-onset type 2 diabetes (NoD) is associated with subsequent diagnosis of PDAC in observational studies and may afford an opportunity...
5.
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
Heilig C, Horak P, Kreutzfeldt S, Teleanu V, Mock A, Renner M, et al.
ESMO Open . 2021 Nov; 6(6):100310. PMID: 34808524
Background: Approvals of cancer therapeutics are primarily disease entity specific. Current molecular diagnostic approaches frequently identify actionable alterations in rare cancers or rare subtypes of common cancers for which the...
6.
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
Schlenk R, Weber D, Herr W, Wulf G, Salih H, Derigs H, et al.
Leukemia . 2019 Feb; 33(8):1923-1933. PMID: 30728457
The aim of this randomized phase-II study was to evaluate the effect of substituting cytarabine by azacitidine in intensive induction therapy of patients with acute myeloid leukemia (AML). Patients were...
7.
Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD
Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, et al.
Bone Marrow Transplant . 2017 Jun; 52(10):1399-1405. PMID: 28650448
There is increasing evidence that endothelial dysfunction is involved in refractoriness of acute GvHD (aGvHD). Here we investigated the hypothesis that another endothelial complication, transplant-associated thrombotic microangiopathy (TMA), contributes to...
8.
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, et al.
Blood Cancer J . 2017 May; 7(5):e564. PMID: 28548643
The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given...
9.
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
Kayser S, Krzykalla J, Elliott M, Norsworthy K, Gonzales P, Hills R, et al.
Leukemia . 2017 Mar; 31(11):2347-2354. PMID: 28322237
Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL...
10.
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
Wattad M, Weber D, Dohner K, Krauter J, Gaidzik V, Paschka P, et al.
Leukemia . 2017 Feb; 31(6):1306-1313. PMID: 28138160
We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between 1993 and 2009, 3324 patients with newly diagnosed...